546 related articles for article (PubMed ID: 17846007)
41. Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer.
Aita M; Fasola G; Defferrari C; Brianti A; Bello MG; Follador A; Sinaccio G; Pronzato P; Grossi F
Crit Rev Oncol Hematol; 2008 Dec; 68(3):183-96. PubMed ID: 18606548
[TBL] [Abstract][Full Text] [Related]
42. Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer.
Köhne CH; Lenz HJ
Oncologist; 2009 May; 14(5):478-88. PubMed ID: 19411318
[TBL] [Abstract][Full Text] [Related]
43. Neoadjuvant treatment of colorectal cancer with bevacizumab: the perioperative angiogenic balance is sensitive to systemic thrombospondin-1 levels.
Brostjan C; Gebhardt K; Gruenberger B; Steinrueck V; Zommer H; Freudenthaler H; Roka S; Gruenberger T
Clin Cancer Res; 2008 Apr; 14(7):2065-74. PubMed ID: 18381946
[TBL] [Abstract][Full Text] [Related]
44. Integration of anti-vascular endothelial growth factor therapies with cytotoxic chemotherapy in the treatment of colorectal cancer.
Oliveira SC; Machado KK; Sabbaga J; Hoff PM
Cancer J; 2010; 16(3):220-5. PubMed ID: 20526100
[TBL] [Abstract][Full Text] [Related]
45. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab.
Scappaticci FA; Fehrenbacher L; Cartwright T; Hainsworth JD; Heim W; Berlin J; Kabbinavar F; Novotny W; Sarkar S; Hurwitz H
J Surg Oncol; 2005 Sep; 91(3):173-80. PubMed ID: 16118771
[TBL] [Abstract][Full Text] [Related]
46. Overview of anti-VEGF therapy and angiogenesis. Part 1: Angiogenesis inhibition in solid tumor malignancies.
Ellis LM; Rosen L; Gordon MS
Clin Adv Hematol Oncol; 2006 Jan; 4(1):suppl 1-10; quz 11-2. PubMed ID: 16562372
[TBL] [Abstract][Full Text] [Related]
47. The horizon of antiangiogenic therapy for colorectal cancer.
Olszewski AJ; Grossbard ML; Kozuch PS
Oncology (Williston Park); 2005 Mar; 19(3):297-306; discussion 306, 308, 317-33. PubMed ID: 15828549
[TBL] [Abstract][Full Text] [Related]
48. Spotlight on bevacizumab in metastatic colorectal cancer.
McCormack PL; Keam SJ
BioDrugs; 2008; 22(5):339-41. PubMed ID: 18778115
[TBL] [Abstract][Full Text] [Related]
49. The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab.
Marty M; Pivot X
Eur J Cancer; 2008 May; 44(7):912-20. PubMed ID: 18396037
[TBL] [Abstract][Full Text] [Related]
50. Fournier's gangrene as a possible side effect of bevacizumab therapy for resected colorectal cancer.
Gamboa EO; Rehmus EH; Haller N
Clin Colorectal Cancer; 2010 Jan; 9(1):55-8. PubMed ID: 20100690
[TBL] [Abstract][Full Text] [Related]
51. Bevacizumab in the treatment of colorectal cancer.
Mulcahy MF; Benson AB
Expert Opin Biol Ther; 2005 Jul; 5(7):997-1005. PubMed ID: 16018743
[TBL] [Abstract][Full Text] [Related]
52. Antivascular endothelial growth factor monoclonal antibody therapy: a promising paradigm in colorectal cancer.
Franson PJ; Lapka DV
Clin J Oncol Nurs; 2005 Feb; 9(1):55-60. PubMed ID: 15751499
[TBL] [Abstract][Full Text] [Related]
53. Adverse events associated with antiangiogenic agents in combination with cytotoxic chemotherapy in metastatic colorectal cancer and their management.
Cartwright TH
Clin Colorectal Cancer; 2013 Jun; 12(2):86-94. PubMed ID: 23562587
[TBL] [Abstract][Full Text] [Related]
54. Bevacizumab and ovarian cancer.
Sato S; Itamochi H
Curr Opin Obstet Gynecol; 2012 Feb; 24(1):8-13. PubMed ID: 22123222
[TBL] [Abstract][Full Text] [Related]
55. Targeting vascular endothelial growth factor in colorectal cancer.
Berlin JD
Oncology (Williston Park); 2002 Aug; 16(8 Suppl 7):13-5. PubMed ID: 12199627
[TBL] [Abstract][Full Text] [Related]
56. [Aflibercept (Zaltrap(®)) approved in metastatic colorectal cancer].
André T; Chibaudel B
Bull Cancer; 2013 Oct; 100(10):1023-5. PubMed ID: 24047539
[TBL] [Abstract][Full Text] [Related]
57. Safety of bevacizumab in patients with metastatic breast cancer.
Hamilton EP; Blackwell KL
Oncology; 2011; 80(5-6):314-25. PubMed ID: 21778772
[TBL] [Abstract][Full Text] [Related]
58. Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies.
Zondor SD; Medina PJ
Ann Pharmacother; 2004; 38(7-8):1258-64. PubMed ID: 15187215
[TBL] [Abstract][Full Text] [Related]
59. The evolving role of VEGF-targeted therapies in the treatment of metastatic colorectal cancer.
Fakih M
Expert Rev Anticancer Ther; 2013 Apr; 13(4):427-38. PubMed ID: 23432698
[TBL] [Abstract][Full Text] [Related]
60. [Antibody treatment in colorectal cancer--what the surgeon needs to know].
Thalheimer A; Illert B; Reimer P; Bueter M; Thiede A; Gasser M; Fein M; Waaga-Gasser AM; Meyer D
Zentralbl Chir; 2008 Apr; 133(2):101-6. PubMed ID: 18415895
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
